Anavex restates FY2025 internal control audit opinion, posts net loss of $46.38 million

Reuters2026/08/28 20:25

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Anavex Life Sciences filed a 10-K/A with audited results for fiscal 2025, updating controls reporting tied to an internal control material weakness.
Grant Thornton’s audit kept an unqualified opinion on the consolidated financial statements, citing fair presentation under US GAAP.
The auditor issued an adverse opinion on internal control over financial reporting as of Sept. 30, 2025, replacing a prior unqualified view.
Net loss was USD 46.38 million, or USD 0.54 per share; cash and cash equivalents ended at USD 102.58 million.
Management concluded disclosure controls were ineffective at Sept. 30, 2025; financial statements were not changed by the reassessment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anavex Life Sciences Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001731122-26-001164), on August 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Anavex restates FY2025 internal control audit opinion, posts net loss of $46.38 million

You may also like

Crypto prices